Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc., listed on Nasdaq under the ticker UPTD, is a clinical-stage biopharmaceutical company that accessed the public markets through a SPAC transaction, operating in the healthcare and immunotherapy sector. The company filed an 8-K with the SEC on October 5, 2023, reflecting a material corporate event following its de-SPAC closing. Estrella's pipeline centers on novel immunotherapy candidates, placing it within a competitive cohort of biotech-focused blank-check mergers that have drawn significant investor scrutiny in recent years. The filing represents one data point in an active post-merger disclosure record for the company. For the full UPTD deal timeline, sponsor details, shareholder vote results, and warrant activity, sign up for complete data access at SpacDesk.